The demand for GLP-1 receptor subcutaneous treatments for obesity has led to a lucrative market, driving the development of oral alternatives.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing
Four oral GLP-1R products in Phase III trials as race intensifies
